In agreement with these data, DTX2 was recently identified as one of the top PARPi-sensitizing hits in genome-wide CRISPR screens in two out of four examined BRCA1/2-proficient prostate cancer cell lines (22Rv1 and DU145) (102). This evidence concerns the gene BRCA1 and prostate carcinoma.